SOURCE: Xtalks

Xtalks Webinars

November 29, 2016 07:00 ET

New Webinar Hosted by Xtalks with Late Breaking Data from the Society for Immunotherapy of Cancer 2016

Combinatorial CD8+ and PDL1+ Cell Densities Correlate with Response and Improved Survival in NSCLC Patients Treated with Durvalumab

TORONTO, ON--(Marketwired - November 29, 2016) - The presentation represents the team effort of groups at DEFINIENS and MedImmune and was recently presented at the SITC conference. Join industry expert Sonja Althammer, Bioinformatics Team Lead at Definiens, online on Tuesday, December 6, 2016 as she demonstrates:

  • How Tissue Phenomics® can support you to quantify different cell populations based on multiple biomarker expression profiles (CD8(+) and PD-L1(+)) and to further investigate correlations of the density of those populations to the clinical data
  • How Tissue Phenomics® has been used to detect the improved predictive value for Durvalumab treatment by combining CD8 and PD-L1 evaluation compared to PD-L1 alone.

Immunotherapies have improved patient responses and survival, though not all patients benefit. Effective biomarkers may help improve outcomes. Durvalumab is a human IgG1 monoclonal antibody that inhibits programmed death ligand-1 (PD-L1) binding to programmed death-1 and B7.1/CD80, restoring antitumor immunity. PD-L1 expression on tumor or tumor-infiltrating immune cells measured manually with different immunohistochemistry (IHC) assays can enrich for patients responding to anti-PD1/PD-L1 agents. Tumor-infiltrating cytotoxic CD8+ T cells may also have potential predictive utility for therapeutic response. We explored automated image analysis and pattern recognition of tumor biopsies to determine whether CD8+ and PD-L1+ cells densities could better identify patients most likely to respond to durvalumab than PD-L1 IHC alone.


Patients with high pretreatment CD8+ and PDL1+ densities (prevalence=36%) had better ORR, OS, and PFS compared to those with low CD8+ and PDL1+ densities, as well as high PDL1 expression alone.


Automated image analysis of CD8+ and PDL1+ cell densities in baseline tumor biopsies may identify patients with improved outcomes to durvalumab.

To learn more about this event visit: Late Breaking Data from the Society for Immunotherapy of Cancer 2016

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners (from pharmaceutical & biotech companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit

For information about hosting a webinar visit

Image Available:

Contact Information